Edwards Lifesciences (EW) has been back in focus after moving to sell its critical care unit and to concentrate on areas such as asymptomatic aortic stenosis and structural heart failure, along with fresh Q4 numbers.

The recent decision to sell the critical care unit, Q4 results, and the appointment of a new Director of Government Affairs have all come as Edwards Lifesciences posts a 10.79% 1 month share price return and a 24.20% 1 year total shareholder return, suggesting sentiment has been improving rather than fading.

If this refocus on core heart therapies has your attention, it may be a suitable moment to broaden your watchlist with our screener of 34 healthcare AI stocks as potential next ideas to research.

With Edwards Lifesciences posting revenue of US$6.07b, net income of US$1.06b, and a recent share price around US$85, the key question is simple: is there still value on the table, or is the market already pricing in future growth?

Most Popular Narrative: 11.8% Undervalued

Edwards Lifesciences last closed at about $85, while the most followed narrative sets fair value closer to $96, framing the stock as modestly undervalued on its long term cash flow potential.

The expected approval of the early TAVR indication in the second quarter, along with policy and guideline changes in the U.S. and globally, represents a multiyear growth opportunity that could significantly enhance revenue streams in the future. The planned launch of the transcatheter tricuspid valve EVOQUE in 2024 is anticipated to uniquely position Edwards to gain market share and increase revenues as it becomes the first company to develop and offer this therapy.

Curious what kind of revenue path and profit margins have to line up for that valuation gap to make sense? The narrative leans on steady top line expansion, firmer earnings power, and a richer future earnings multiple than many peers. Want to see exactly how those ingredients are combined to reach that fair value number?

Result: Fair Value of $96.46 (UNDERVALUED)

However, there are still important watchpoints, including tariff pressures on margins and the risk that new product launches or indication expansions take longer to gain traction.

Another Angle on Valuation

Our DCF work suggests Edwards Lifesciences is around 5.2% below fair value, with the shares at about $85 versus an estimated future cash flow value near $89.72. That still points to some upside, but it is far tighter than the $96 narrative. Which view feels more realistic to you?

Next Steps

Given the mix of optimism and caution in this story, it makes sense to review the numbers yourself and decide where you stand, starting with 2 key rewards and 3 important warning signs.

Looking for more investment ideas?

Before you move on, give yourself a stronger lineup of candidates by scanning a few focused stock lists that can help you spot opportunities you might otherwise miss.

• Target potential value opportunities by reviewing our list of 50 high quality undervalued stocks that currently screen well on price and business quality.
• Strengthen your downside protection by checking out 67 resilient stocks with low risk scores, featuring companies that score well on our risk measures.
• Get ahead of the crowd by researching our screener containing 23 high quality undiscovered gems, where smaller, less followed names still show solid fundamentals.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.